Puma Biotechnology Inc
$ 7.05
2.92%
09 Jun - close price
- Market Cap 348,661,000 USD
- Current Price $ 7.05
- High / Low $ 7.09 / 6.85
- Stock P/E 14.27
- Book Value 2.52
- EPS 0.48
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.22 %
- 52 Week High 7.90
- 52 Week Low 3.03
About
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and internationally. The company is headquartered in Los Angeles, California.
Analyst Target Price
$5.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-29 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -0.04 | 0.29 | 0.21 | 0.15 | 0.06 | 0.43 | 0.45 | -0.05 | -0.05 | 0.26 | 0.17 | 0.1 |
| Estimated EPS | -0.13 | 0.27 | 0.09 | 0.07 | -0.02 | 0.14 | 0.38 | -0.1 | -0.15 | 0.3 | 0.14 | 0.07 |
| Surprise | 0.09 | 0.02 | 0.12 | 0.08 | 0.08 | 0.29 | 0.07 | 0.05 | 0.1 | -0.04 | 0.03 | 0.03 |
| Surprise Percentage | 69.2308% | 7.4074% | 133.3333% | 114.2857% | 400% | 207.1429% | 18.4211% | 50% | 66.6667% | -13.3333% | 21.4286% | 42.8571% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.07 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PBYI
2026-06-04 06:40:10
Puma Biotechnology, Inc. announced the grant of inducement restricted stock unit awards totaling 7,000 shares of common stock to two new non-executive employees. These awards were made under Puma's 2017 Employment Inducement Incentive Award Plan and vest over a three-year period, subject to continued service. The grants were inducement material for employment, aligning with Nasdaq Listing Rule 5635(c)(4).
2026-06-03 21:39:39
Puma Biotechnology announced inducement awards granted under Nasdaq Listing Rule 5635(c)(4). These awards are a common mechanism for publicly traded companies to attract and retain employees outside of traditional stock option plans. The brief report was distributed by Refinitiv.
2026-05-15 12:11:23
Puma Biotechnology's recent earnings announcement was disappointing on the surface, but a deeper analysis reveals positive underlying factors. The company recorded a strong negative accrual ratio of -0.60, indicating excellent cash conversion where free cash flow significantly exceeded statutory profit. This suggests Puma Biotechnology's true earnings potential might be better than initial reports, further bolstered by strong EPS growth.
2026-05-15 08:11:23
This article provides news headlines related to Puma Biotechnology Inc (PBYI), including recent earnings reports, analyst coverage, and other significant company updates. Key information includes their Q1 2026 earnings call transcript, Q1 2026 revenue of $44.8 million, and a raise in full-year guidance for 2026. The article also lists past earnings dates and mentions related industry news.
2026-05-12 07:40:59
The article reports that PBYI's Q1 earnings and sales have surpassed analyst estimates. In response to the strong performance, the company has also increased its financial guidance for the year 2026. This positive news suggests a strong outlook for PBYI.
2026-05-11 13:10:17
Puma Biotechnology, Inc. (NASDAQ:PBYI) recently reported strong first-quarter results with revenues exceeding analyst forecasts. Despite lowered earnings per share estimates for 2026, the analyst has raised the price target, suggesting a positive long-term outlook. However, the company faces anticipated revenue decline faster than industry peers.
